All lobbying filings

DAIICHI SANKYO, INC.

DAIICHI SANKYO, INC. filed a Q4 report for DAIICHI SANKYO INC on January 20, 2026.

Lobbying for DAIICHI SANKYO INC

All filings by DAIICHI SANKYO, INC. · Everything DAIICHI SANKYO INC has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$90,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction

Taxation/Internal Revenue Code

Discussions regarding tax reform and tariffs

Bills named in this filing 2

H.R. 946
ORPHAN Cures Act
H.R. 2319
Women and Lung Cancer Research and Preventive Services Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.